Don W. Kassing Sells 170 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Don W. Kassing sold 170 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $179.99, for a total value of $30,598.30. Following the transaction, the director now directly owns 1,005 shares in the company, valued at approximately $180,889.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Penumbra Trading Up 0.8 %

Penumbra stock opened at $177.44 on Thursday. Penumbra, Inc. has a 52-week low of $170.59 and a 52-week high of $341.23. The company has a quick ratio of 3.51, a current ratio of 6.12 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $6.88 billion, a price-to-earnings ratio of 74.87, a PEG ratio of 1.78 and a beta of 0.55. The firm has a 50-day moving average price of $192.82 and a two-hundred day moving average price of $224.55.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.01). Penumbra had a return on equity of 7.83% and a net margin of 8.52%. The business had revenue of $278.70 million for the quarter, compared to analyst estimates of $274.94 million. During the same quarter in the prior year, the firm posted $0.23 earnings per share. The business’s quarterly revenue was up 15.5% on a year-over-year basis. Sell-side analysts expect that Penumbra, Inc. will post 2.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Piper Sandler decreased their price objective on shares of Penumbra from $290.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, May 8th. Needham & Company LLC restated a “hold” rating on shares of Penumbra in a research report on Wednesday, May 8th. Truist Financial decreased their price target on shares of Penumbra from $290.00 to $280.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Finally, Canaccord Genuity Group dropped their price objective on shares of Penumbra from $284.00 to $272.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $293.10.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Penumbra by 171.8% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock valued at $27,000 after purchasing an additional 67 shares during the period. Mather Group LLC. bought a new position in Penumbra in the 1st quarter valued at about $29,000. Signaturefd LLC increased its stake in Penumbra by 27.2% during the 4th quarter. Signaturefd LLC now owns 215 shares of the company’s stock valued at $54,000 after buying an additional 46 shares during the period. Quest Partners LLC bought a new stake in shares of Penumbra during the 4th quarter worth about $71,000. Finally, Picton Mahoney Asset Management bought a new stake in shares of Penumbra during the 4th quarter worth about $88,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.